venBio Partners

Established in 2011, venBio is a life science venture capital firm that focuses on novel therapeutics for unmet medical needs. Since inception in 2011, venBio has raised nearly $1.5 billion in capital commitments and led investment rounds in 34 companies, including: venBio-founded Labrys Biologics (acquired by Teva) and ALX Oncology (NASDAQ: ALXO); Aragon Pharmaceuticals (acquired by Johnson & Johnson); Seragon Pharmaceuticals (acquired by Roche); Aurinia Pharmaceuticals (NASDAQ: AUPH); Apellis Pharmaceuticals (NASDAQ: APLS); Turning Point Therapeutics (NASDAQ: TPTX); Precision Biosciences (NASDAQ: DTIL); Akero Therapeutics (NASDAQ: AKRO); Harmony Biosciences (NASDAQ: HRMY); and Pharvaris (NASDAQ: PHVS).